Evidence map›Paper›PMID 36797233›Full record

Trial reportTranslational psychiatry2023

Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI.

Arnim J Gaebler, Nilüfer Fakour, Felix Stöhr, Jana Zweerings, Arezoo Taebi, Mariia Suslova, Juergen Dukart, Joerg F Hipp, Bhim M Adhikari, Peter Kochunov and 9 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Translational psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 26 citations in OpenAlex.

  1. Gut microbiota: contributing to high CVD prevalence in people living with schizophrenia?European archives of psychiatry and clinical neuroscience · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Current neuropharmacology · 2025
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 4 countries.

Arnim J GaeblerDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany. agaebler@ukaachen.de.ORCID 0000-0002-8816-3415
Nilüfer FakourDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Felix StöhrDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Jana ZweeringsDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Arezoo TaebiDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Mariia SuslovaDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Juergen DukartF. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.
Joerg F HippF. Hoffmann-La Roche, Pharma Research Early Development, Roche Innovation Centre Basel, Basel, Switzerland.ORCID 0000-0002-7875-2988
Bhim M AdhikariMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Peter KochunovMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Suresh D MuthukumaraswamySchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.ORCID 0000-0001-7042-3920
Anna ForsythSchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand.
Thomas EggermannInstitute for Human Genetics and Genomic Medicine, Faculty of Medicine, RWTH Aachen, Aachen, Germany.ORCID 0000-0002-8419-0264
Florian KraftInstitute for Human Genetics and Genomic Medicine, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Ingo KurthInstitute for Human Genetics and Genomic Medicine, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Michael PaulzenDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.
Gerhard GründerCentral Institute of Mental Health, Department of Molecular Neuroimaging, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Frank SchneiderUniversity Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany.
Klaus MathiakDepartment of Psychiatry, Psychotherapy and Psychosomatics, Faculty of Medicine, RWTH Aachen, Aachen, Germany.ORCID 0000-0002-2276-7726
Brain (Germany) · DERWTH Aachen University · DERoche (Switzerland) · CHUniversity of Auckland · NZUniversity of Maryland, Baltimore · USDüsseldorf University Hospital · DEHeidelberg University · DEUniversitätsklinikum Aachen · DE

Funding

SOLAR-Eclipse Computational Tools for Imaging GeneticsR01EB015611 · NIBIB · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KOCHUNOV, PETER V. · 2012 to 2024
$5.0M
Redefine Trans-Neuropsychiatric Disorder Brain Patterns through Big-Data and Machine LearningRF1MH123163 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI KOCHUNOV, PETER V., THOMPSON, PAUL M · 2021 to 2021
$1.2M
Hybrid GPU/CPU Computing Resource to Support Connectomic and GenomicsS10OD023696 · OD · UNIVERSITY OF MARYLAND BALTIMORE · PI KOCHUNOV, PETER V. · 2018 to 2018
$593k
NIBIB NIH HHS R01 EB015611NIH HHS S10 OD023696NIMH NIH HHS RF1 MH123163
6 · The paper itself

Abstract

Both, pharmacological and genome-wide association studies suggest N-methyl-D-aspartate receptor (NMDAR) dysfunction and excitatory/inhibitory (E/I)-imbalance as a major pathophysiological mechanism of schizophrenia. The identification of shared fMRI brain signatures of genetically and pharmacologically induced NMDAR dysfunction may help to define biomarkers for patient stratification. NMDAR-related genetic and pharmacological effects on functional connectivity were investigated by integrating three different datasets: (A) resting state fMRI data from 146 patients with schizophrenia genotyped for the disease-associated genetic variant rs7191183 of GRIN2A (encoding the NMDAR 2 A subunit) as well as 142 healthy controls. (B) Pharmacological effects of the NMDAR antagonist ketamine and the GABA-A receptor agonist midazolam were obtained from a double-blind, crossover pharmaco-fMRI study in 28 healthy participants. (C) Regional gene expression profiles were estimated using a postmortem whole-brain microarray dataset from six healthy donors. A strong resemblance was observed between the effect of the genetic variant in schizophrenia and the ketamine versus midazolam contrast of connectivity suggestive for an associated E/I-imbalance. This similarity became more pronounced for regions with high density of NMDARs, glutamatergic neurons, and parvalbumin-positive interneurons. From a functional perspective, increased connectivity emerged between striato-pallido-thalamic regions and cortical regions of the auditory-sensory-motor network, while decreased connectivity was observed between auditory (superior temporal gyrus) and visual processing regions (lateral occipital cortex, fusiform gyrus, cuneus). Importantly, these imaging phenotypes were associated with the genetic variant, the differential effect of ketamine versus midazolam and schizophrenia (as compared to healthy controls). Moreover, the genetic variant was associated with language-related negative symptomatology which correlated with disturbed connectivity between the left posterior superior temporal gyrus and the superior lateral occipital cortex. Shared genetic and pharmacological functional connectivity profiles were suggestive of E/I-imbalance and associated with schizophrenia. The identified brain signatures may help to stratify patients with a common molecular disease pathway providing a basis for personalized psychiatry.

Indexed as

KetamineSchizophreniaGenome-Wide Association StudyHumansMagnetic Resonance ImagingMidazolamReceptors, N-Methyl-D-AspartateKetamineMidazolamReceptors, N-Methyl-D-Aspartate

Identifiers

PMID36797233
PMCPMC9935542
OpenAlexW4321104034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.